Patents by Inventor Vishnumurthy Hegde
Vishnumurthy Hegde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122058Abstract: Provided is a deuterated compound produced by a method that includes: heating a first compound in a solvent containing a deuterated material to an elevated temperature to generate the deuterated compound; and isolating the deuterated compound; where the first compound has at least 0.01 mg/mL solubility in the deuterated material at 25° C. Further provided are OLEDs and consumer products containing the deuterated compound.Type: ApplicationFiled: August 16, 2023Publication date: April 11, 2024Applicant: Universal Display CorporationInventors: Bert Alleyne, Venugopal Gudipati, Vishnumurthy Hegde, Pierre-Luc T. Boudreault
-
Publication number: 20230279021Abstract: Crystalline forms of a GABAA ?5 agonist, pharmaceutical compositions and combinations comprising those crystalline forms, their use in methods of treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancer, the brain cancer itself or Parkinson's disease psychosis and methods of producing the crystalline forms.Type: ApplicationFiled: July 9, 2021Publication date: September 7, 2023Inventors: Deepa Gandla, Brian Gregg, Vishnumurthy Hegde, Stephan D. Parent, Travis Lee Houston
-
Patent number: 11116816Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: GrantFiled: January 29, 2019Date of Patent: September 14, 2021Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20210008153Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: July 3, 2020Publication date: January 14, 2021Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10702574Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: February 11, 2017Date of Patent: July 7, 2020Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10420819Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: March 23, 2017Date of Patent: September 24, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 10406202Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: GrantFiled: July 12, 2018Date of Patent: September 10, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20190183966Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: ApplicationFiled: January 29, 2019Publication date: June 20, 2019Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20180311307Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: ApplicationFiled: July 12, 2018Publication date: November 1, 2018Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9789197Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: October 17, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20170252410Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: March 23, 2017Publication date: September 7, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20170216449Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: February 11, 2017Publication date: August 3, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9616109Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: April 11, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 9585934Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: March 7, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160114001Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20160113993Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160114049Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20140024807Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: March 28, 2013Publication date: January 23, 2014Applicant: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20130245241Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: SALADAX BIOMEDICAL INC.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
-
Patent number: 8450461Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.Type: GrantFiled: November 29, 2011Date of Patent: May 28, 2013Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
